Novel Agent Fails to Show Sufficient Activity in Recurrent OsteosarcomaNovember 14th 2017
The GPNMB-targeted agent known as glembatumumab vedotin was reasonably well tolerated and showed some activity in a phase II study of recurrent/refractory osteosarcoma, but this activity was not enough to continue the drug’s evaluation in this setting based on the study protocol.
Aftercare in Sarcoma Should Incorporate Time- and Risk-Adjusted StrategiesNovember 12th 2017
An analysis of more than 800 patients found that the one-size-fits-all approach to “aftercare” for localized soft-tissue sarcoma is misguided. Local recurrence and distant metastasis occur in a non-constant fashion in the years after treatment, and a time- and risk-adapted strategy for aftercare is warranted.
Combined Immunotherapy Shows Promise in Certain Sarcoma SubtypesNovember 10th 2017
The combination of durvalumab and tremelimumab offered a modest response rate in unselected patients with heavily pretreated metastatic sarcoma, but higher rates were seen in specific subtypes, including angiosarcoma and alveolar soft-part sarcoma.
T-Cell Therapy With Fludarabine Active in Synovial SarcomaNovember 10th 2017
NY-ESO-1 SPEAR T-cell therapy showed promising results and was reasonably safe in patients with synovial sarcoma, according to a new study. The addition of fludarabine may be important to achieving those positive results.
Isolated Limb Perfusion for Advanced Angiosarcoma Offers High Limb Salvation RateNovember 9th 2017
Isolated limb perfusion with high-dose melphalan and TNF-alpha has a high response rate and results in good survival outcomes in patients with locally advanced angiosarcoma, according to results of a new study.
Axitinib/Pembrolizumab Shows Promising Results in Alveolar Soft-Part SarcomaNovember 9th 2017
The combination of axitinib and pembrolizumab was reasonably well tolerated and showed promising activity in patients with various subtypes of soft-tissue sarcoma, with the benefit seen primarily in those with alveolar soft-part sarcoma, according to a new study.